Knowledge center

The place to find all the most innovative research and information on novel biologics and biosimilars.

Press Releases

Polpharma Biologics Group announces that the Biologics License Application (BLA) submitted by its joint venture Bioeq for its biosimilar Ranibizumab has been accepted for review by the U.S. Food and Drug Administration (FDA)

Bioeq has received notification by the U.S. Food and Drug Administration (FDA) that the biologics license application (BLA) for its proposed biosimilar to Lucentis® has been accepted for review.


You can find all the latest presentations, brochures and fact sheets below covering our solutions and portfolio.

Let’s collaborate and deliver quality biosimilars together.

Get in touch for more information.